Global /South Korea /Healthcare /Biotechnology /142760

MOA Life Plus Co. Ltd.

142760

• KRX: 142760 • Delayed

870KRW 0%

0.5700 USD

As of 13 June 2026, MOA Life Plus Co. Ltd. has a market cap of $24.12M USD, ranking #35766 globally and #2243 in South Korea. It ranks #3218 in the Healthcare sector, and #624 in the Biotechnology industry.

Global Rank

35766

Country Rank

2243

Sector Rank

3218

Industry Rank

624

Key Stats

Market Cap

$24.12MUSD

36.69B KRW

Enterprise Value

$22.96MUSD

35.04B KRW

Revenue (TTM)

$7.38MUSD

11.22B KRW

EBITDA (TTM)

-$4.18MUSD

-6.37B KRW

Net Income (TTM)

-$8.58MUSD

-13.05B KRW

EBITDA Margin

-57%

Profit Margin

-116%

PS Ratio

3.3

PB Ratio

1.2

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Biotechnology

CEO

Park Young Chul open_in_new

Employees

Founded

1999

Website

moalifeplus.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	-5.1%	-8.2%	-45%	-50%	-51%	-32%	-80%	-84%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	142760 모아라이프플러스(주) ISIN: KR7142760008 Shares Out.: Shares Outstanding: 42.167M¹ Shares Float: 32.647M² TV: TradingView: KRX: 142760 SA: Stock Analysis: KRX: 142760 YF: Yahoo Finance: 142760.KS GF: Google Finance: KRX: 142760 BA: Barron's: 142760 MS: Morningstar: XKRX: 142760	870 KRW	TV: TradingView: KRX: 142760 SA: Stock Analysis: KRX: 142760 YF: Yahoo Finance: 142760.KS GF: Google Finance: KRX: 142760 BA: Barron's: 142760 MS: Morningstar: XKRX: 142760

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About MOA Life Plus Co. Ltd.

MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company’s pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw materials, and cosmetics. The company was formerly known as Bioleaders Corporation and changed its name to MOA Life Plus Co. Ltd. in March 2024. MOA Life Plus Co. Ltd. was founded in 1999 and is headquartered in Yongin-Si, South Korea.

Similar Companies

Industry: Biotechnology (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 186K%	35.5	South Korea
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 116K%	43.8	South Korea
ALTEOGEN Inc. KRX: 196170	$13.37B 20.33T KRW 55K%	146.6	South Korea
HLB Co., Ltd. KRX: 028300	$5.51B 8.37T KRW 23K%	-	South Korea
Peptron, Inc. KRX: 087010	$3.99B 6.07T KRW 16K%	-	South Korea
SK bioscience Co.,Ltd. KRX: 302440	$2.25B 3.42T KRW 9K%	-	South Korea

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 756K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 663K%	19.0	United States
argenx SE EBR: ARGX	$47.84B 41.39B EUR 198K%	39.9	Netherlands
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 176K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 175K%	37.2	Switzerland
Natera, Inc. NASDAQ: NTRA	$27.6B 114K%	-	United States

chevron_leftBack